Both Aflibercept and Vabysmo offer similar effectiveness in symptom control, with the main difference being how quickly they act. Either drug is a viable option depending on the patient’s needs.

Vabysmo is gentler on the liver and kidneys and has a better safety profile for long-term use, particularly for older patients or those with pre-existing conditions.

Both Aflibercept and Vabysmo have a low risk of addiction when used correctly under medical supervision, with minimal potential for misuse.

Both Aflibercept and Vabysmo are easy to use, with straightforward dosing regimens that ensure good adherence.

Both Aflibercept and Vabysmo have some contraindications based on individual health conditions, but neither has significantly more restrictions than the other.

Both drugs offer advantages depending on treatment goals. Aflibercept is great for fast relief, while Vabysmo is better for long-term management. The choice depends on the patient’s specific needs.